UPLYFT For Lymphoma Survivors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDana-Farber Cancer Institute
About this trial
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
Age ≥ 18 years
Interval of 3 months to 24 months from completion of first-line treatment
In complete remission after first line of treatment
Disqualifiers
Age < 18 years
Concurrent other malignancy
Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).
Age < 18 years
Trial design
Design model
Parallel
Treatments tested in this trial
Interview with Clinicians
Other interventionOne time, qualitative interview of clinicians for feedback on UPLYFT intervention
Field Test of UPLYFT with Lymphoma Survivors
Other intervention6 session of UPLYFT intervention with Lymphoma Survivors for feedback
Pilot of UPLYFT with Lymphoma Survivors
Behavioral6 session of UPLYFT intervention with Lymphoma Survivors
Treatment groups
74 Participants
are divided into 3 treatment groupsGroup A: Clinicians InterviewsExperimental treatment 1 intervention
Group B: Lymphoma Survivors Field TestExperimental treatment 1 intervention
Group C: UPLYFT PilotExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Feasibility: Enrollment Rate
Proportion of eligible patients approached that enroll in the study.
Time frame
Up to 6 months2
Feasibility: Program Session Completion Rate
Proportion of study participants randomized to the intervention arm (UPLYFT) who complete all intervention sessions.
Time frame
Up to 6 months3
Feasibility: Data Collection Completion Rate
Proportion of enrolled participants who complete assigned patient-reported questionnaires during the study.
Time frame
Up to 6 monthsSecondary outcomes
1
Acceptability: Satisfaction Rate
Satisfaction rate is defined as the proportion of study participants randomized to the intervention arm who are satisfied with the UPLYFT program and proportion who are likely to recommend the program.
Time frame
Up to 6 months2
Acceptability: Disenrollment Rate
Disenrollment rate is defined as the proportion of eligible patients who enroll in the study who then choose to disenroll from the study.
Time frame
Up to 6 months3
Preliminary efficacy: Fear of Cancer Recurrence (FCR) Change
Pre-intervention to post-intervention changes in Fear of Cancer Recurrence (FCR) measured with the Fear of Cancer Recurrence Inventory (FCRI, 42-item questionnaire), with a focus on the FCRI severity subscale.
Time frame
Up to 6 months4
Preliminary efficacy: Quality of Life Change
Pre-intervention to post-intervention changes in quality of life measured with the Quality of Life- Cancer Survivor instrument (a 41-item questionnaire)
Time frame
Up to 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Dana-Farber Cancer Institute
Lead sponsor
American Society of Hematology
Collaborator
Source ClinicalTrials.gov